🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#LegendNews: Legend Biotech will host a webcast to announce 2025 first-quarter financial results on May 13 at 8 a.m. ET. Register to join here: investors.legendbiotech.com/news-releases/… $LEGN #WeAreLegend #FinancialResults

It’s #OncologyNursingMonth, and we’re celebrating the extraordinary oncology nurses on the front lines of patient care. We witness the crucial role these #HealthcareHeroes play in the fight against cancer; we’re honored to work alongside such dedicated professionals. #CancerCare

We are thrilled to announce Legend Biotech is an official partner of @NerdlandBe Festival 2025! 🔬We can't wait to connect with fellow #Science enthusiasts, families, and the vibrant #Nerdland community. Check out our lineup of Legendary speakers: legendbiotech.eu/nerdlandfestiv…

#LegendNews: Today, we shared our 2025 first-quarter financial results, with insights from our CEO, Ying Huang. Read the highlights and more here: investors.legendbiotech.com/news-releases/… #CellTherapy #CART

We are thrilled to announce that our #CART #CellTherapy for patients with #MultipleMyeloma has achieved a record-high manufacturing success rate of 97% at our facility in Raritan, NJ. At Legend Biotech, we push beyond boundaries every day to advance our transformational therapy.

#LegendNews: Join us Sunday, June 1, 6 p.m. CT (7 p.m. ET) at ASCO Annual Meeting for Legend Biotech’s Investor Event in Chicago. Hear the latest on our clinical progress and #CellTherapy pipeline. investors.legendbiotech.com/news-releases/… #ASCO25 #Investors #Biotech #CART $LEGN

#LegendNews: Our state-of-the-art Tech Lane facility in Belgium has begun clinical production of our #CART #CellTherapy! Here's to a future where more patients can benefit from the transformative potential of cell therapy! 🚀

Our CEO, Ying Huang, spoke with Genetic Engineering & Biotechnology News about our leadership in #CellTherapy for #MultipleMyeloma & how we're expanding access to CAR-T therapies. Learn more: genengnews.com/topics/cancer/… #CART #CellTherapy

We will present long-term data on our #CART therapy for multiple myeloma at ASCO and new data at European Hematology Association. Visit our ASCO exhibit #11113 to learn about our transformative therapy that has treated ~6K patients to date and our work in #SolidTumors. investors.legendbiotech.com/news-releases/…

Today is #WorldBloodCancerDay. At Legend Biotech, we stand in solidarity with patients, families, and healthcare professionals impacted by blood cancers like #MultipleMyeloma. We are committed to advancing transformative therapies that improve patient outcomes. #CellTherapy

The ASCO Annual Meeting begins today! Our CEO, Ying Huang, shares his thoughts on the upcoming conference and previews the abstracts we will present regarding our #CART #CellTherapy for #MultipleMyeloma. If you’re attending, visit us at booth #11113. investors.legendbiotech.com/news-releases/…

#SavetheDate! June 1 is #NationalCancerSurvivorsDay. 🌟 At Legend Biotech, we honor the strength and resilience of cancer survivors. Their journeys inspire our commitment to advancing #CellTherapies for a brighter future and long-term survival. #PatientImpact #CART #CellTherapy

#ICYMI: Our CEO, Dr. Ying Huang, met with BiotechTV at #ASCO25 to discuss new long-term OS data from our #CART #CellTherapy trials to treat #MultipleMyeloma, expanding pipeline for #SolidTumors and more. Watch now: bit.ly/3ZMsWjD #OncologyInnovation

That’s a wrap on ASCO 2025! ✅ At this year’s meeting, we showcased new data on #CART #CellTherapy in relapsed/refractory #MultipleMyeloma, and presented exciting progress in solid tumors. Thanks to the ASCO community for a productive and collaborative #ASCO2025!

Our #LEGENDary team in Belgium recently took part in the Kom op tegen Kanker cycling challenge to raise support for vital #CancerResearch. 🚴‍♂️ Over 4 days, they pedaled with purpose to cycle 1,000 km. Congrats to the entire team! #WeAreLegend #CyclingForACause

Legend Biotech is at the European Hematology Association 2025 Congress! Join us June 12, 2025, 17:00-18:15 CEST for an encore oral presentation of our groundbreaking five-year survival data for our #CART #CellTherapy in relapsed/refractory #MultipleMyeloma.

Our CEO Dr. Ying Huang met with @OncoDaily at the #ASCO2025 Annual Meeting to discuss the groundbreaking long-term CARTITUDE-1 data generated by our #CART #CellTherapy for #MultipleMyeloma. Watch the full clip: youtu.be/pwsSyv2d_xQ?si…

At #NERDLand2025, our #LEGENDary team connected with future scientists through our CAR-T Showcase Experience & inspiring sessions on the Talent Stage. Our interactive installations shared insights into our work in #CellTherapy and bringing transformative science to patients.

#CARTaccess news: The FDA has removed REMS requirements for BCMA- & CD19-targeted CAR-Ts. This pivotal milestone creates faster access and broader availability in community settings and makes CAR‑T more practical, scalable & patient-centric.